APA (7th ed.) Citation

RH, W. (2026). Disproportionality analysis of pyoderma gangrenosum reporting to the FDA Adverse Event Reporting System in association with antirheumatic biologics. Clinical rheumatology, 45(7), 4609. https://doi.org/10.1007/s10067-026-08237-1

Chicago Style (17th ed.) Citation

RH, Woods. "Disproportionality Analysis of Pyoderma Gangrenosum Reporting to the FDA Adverse Event Reporting System in Association with Antirheumatic Biologics." Clinical Rheumatology 45, no. 7 (2026): 4609. https://doi.org/10.1007/s10067-026-08237-1.

MLA (9th ed.) Citation

RH, Woods. "Disproportionality Analysis of Pyoderma Gangrenosum Reporting to the FDA Adverse Event Reporting System in Association with Antirheumatic Biologics." Clinical Rheumatology, vol. 45, no. 7, 2026, p. 4609, https://doi.org/10.1007/s10067-026-08237-1.